Literature DB >> 18585785

Interaction of human PD-L1 and B7-1.

Manish J Butte1, Victor Peña-Cruz, Mi-Jung Kim, Gordon J Freeman, Arlene H Sharpe.   

Abstract

Numerous studies have pointed to the role of programmed death-1 ligand 1 (PD-L1) in regulating tolerance, chronic infection, and tumor immunity. Recently, we have identified murine B7-1 as a new binding partner for murine PD-L1. Human and mouse B7-1 share only 46% identity, leading us to question whether human B7-1 and PD-L1 can participate in a similar interaction. Here we show that human B7-1 can interact with human PD-L1 with affinity greater than that of B7-1 with CD28, but less than that of B7-1 with CTLA-4 or of PD-L1 with PD-1. We characterize a series of anti-human PD-L1 monoclonal antibodies and identify antibodies that can block interactions of PD-L1 with B7-1, PD-1, or both. Since PD-L1 and CD28 on T cells may compete for B7-1 as a binding partner and CD8 T cells may express high or low levels of CD28, we examined when PD-L1 and CD28 are co-expressed on CD8 T cells. We compared the time-course and extent of PD-L1 induction on CD8 CD28high versus CD28low T cells following stimulation with anti-CD3. We show that PD-L1 is induced to a higher level on CD28high T cells than on CD28low T cells upon activation. These results suggest that PD-L1 may play an important and undervalued role on human T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585785      PMCID: PMC3764616          DOI: 10.1016/j.molimm.2008.05.014

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  20 in total

1.  Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.

Authors:  Mary E Keir; Yvette E Latchman; Gordon J Freeman; Arlene H Sharpe
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 2.  CD28/B7 system of T cell costimulation.

Authors:  D J Lenschow; T L Walunas; J A Bluestone
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

3.  Global analysis of a macromolecular interaction measured on BIAcore.

Authors:  L D Roden; D G Myszka
Journal:  Biochem Biophys Res Commun       Date:  1996-08-23       Impact factor: 3.575

4.  CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics.

Authors:  P A van der Merwe; D L Bodian; S Daenke; P Linsley; S J Davis
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

5.  Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

Authors:  H Nishimura; Y Agata; A Kawasaki; M Sato; S Imamura; N Minato; H Yagita; T Nakano; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

6.  Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Authors:  Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

7.  Differential binding properties of B7-H1 and B7-DC to programmed death-1.

Authors:  Pornpan Youngnak; Yuko Kozono; Haruo Kozono; Hideyuki Iwai; Noriko Otsuki; Hisayo Jin; Ken Omura; Hideo Yagita; Drew M Pardoll; Lieping Chen; Miyuki Azuma
Journal:  Biochem Biophys Res Commun       Date:  2003-08-01       Impact factor: 3.575

Review 8.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

9.  CD28- T lymphocytes. Antigenic and functional properties.

Authors:  M Azuma; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

10.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

View more
  98 in total

1.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Authors:  Jang-June Park; Ryusuke Omiya; Yumiko Matsumura; Yukimi Sakoda; Atsuo Kuramasu; Mathew M Augustine; Sheng Yao; Fumihiko Tsushima; Hidehiko Narazaki; Sudarshan Anand; Yingjia Liu; Scott E Strome; Lieping Chen; Koji Tamada
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

2.  PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

Authors:  Marguerite Ghiotto; Laurent Gauthier; Nacer Serriari; Sonia Pastor; Alemseged Truneh; Jacques A Nunès; Daniel Olive
Journal:  Int Immunol       Date:  2010-06-29       Impact factor: 4.823

3.  DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.

Authors:  Gayatri Mukherjee; Ari Geliebter; Jeffrey Babad; Pere Santamaria; David V Serreze; Gordon J Freeman; Kristin V Tarbell; Arlene Sharpe; Teresa P DiLorenzo
Journal:  Int Immunol       Date:  2013-09-10       Impact factor: 4.823

4.  Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes.

Authors:  Ryoyo Ikebuchi; Satoru Konnai; Tomohiro Okagawa; Kazumasa Yokoyama; Chie Nakajima; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

5.  Identification and characterization of an alternative cancer-derived PD-L1 splice variant.

Authors:  Nadia B Hassounah; Venkat S Malladi; Yi Huang; Samuel S Freeman; Ellen M Beauchamp; Shohei Koyama; Nicholas Souders; Sunil Martin; Glenn Dranoff; Kwok-Kin Wong; Chandra S Pedamallu; Peter S Hammerman; Esra A Akbay
Journal:  Cancer Immunol Immunother       Date:  2018-12-18       Impact factor: 6.968

Review 6.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 7.  Advances in cholangiocyte immunobiology.

Authors:  Gaurav Syal; Michel Fausther; Jonathan A Dranoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-06       Impact factor: 4.052

Review 8.  Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.

Authors:  Guillermo de Velasco; Lana Hamieh; Suzanne Mickey; Toni K Choueiri
Journal:  Urol Oncol       Date:  2015-10-09       Impact factor: 3.498

Review 9.  The complex role of B7 molecules in tumor immunology.

Authors:  Barbara Seliger; Francesco M Marincola; Soldano Ferrone; Hinrich Abken
Journal:  Trends Mol Med       Date:  2008-11-03       Impact factor: 11.951

10.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.

Authors:  Céline Berthon; Virginie Driss; Jizhong Liu; Klaudia Kuranda; Xavier Leleu; Nathalie Jouy; Dominique Hetuin; Bruno Quesnel
Journal:  Cancer Immunol Immunother       Date:  2010-09-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.